A chimeric receptor/oncogene that can be regulated by a ligand in vitro and in vivo

Journal of Clinical Investigation

Volumn 100, Issue 7, 1997, Pages 1708-1715

  Okuda, K ^a   D'Andrea, A ^a   Van Etten, R A ^b   Griffin, J D ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

BCR ABL; Chronic myelogenous leukemia; Erythropoietin; Oncogene

Indexed keywords

CHIMERIC PROTEIN; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; LIGAND; ONCOPROTEIN; RECEPTOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CHROMOSOME 22; CHROMOSOME 9; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOSKELETON; ENZYME ACTIVATION; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN FAMILY;

EID: 0030886766     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI119695     Document Type: Article

References (51)

1. de Klein, A., A.G. van Kessel, G. Grosveld, C.R. Bartram, A. Hagemeijer, D. Bootsma, N.K. Spurr, N. Heisterkamp, J. Groffen, and J.R. Stephenson. 1982. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature (Lond.). 300(5894):765-767.
2. Gabert, J., I. Thuret, Y. Carcassonne, D. Maraninchi, and P. Mannoni. 1990. Residual bcr/abl transcripts in chronic myeloid leukaemia [letter, comment). Lancet. 335(8686):417-418.
3. Groffen, J., J.R. Stephenson, N. Heisterkamp, A. de Klein, C.R. Bartram, and G. Grosveld. 1984. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell. 36(1):93-99.
4. Heisterkamp, N., K. Stam, J. Groffen, A. de Klein, and G. Grosveld. 1985. Structural organization of the bcr gene and its role in the Ph' translocation. Nature (Lond.). 315(6022):758-761.
5. Heisterkamp, N., E. Knoppel, and J. Groffen. 1988. The first BCR gene intron contains breakpoints in Philadelphia chromosome positive leukemia. Nucleic Acids Res. 16(21):10069-10081.
6. Shtivelman, E., B. Lifshitz, R.P. Gale, and E. Canaani. 1985. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature (Lond.) 315(6020):550-554.
7. Stam, K., N. Heisterkamp, G. Grosveld, A. de Klein, R.S. Verma, M. Coleman, H. Dosik, and J. Groffen. 1985. Evidence of a new chimeric bcr/c-abl mRNA in patients with chronic myelocytic leukemia and the Philadelphia chromosome. N. Engl. J. Med. 313(23):1429-1433.
8. Pendergast, A.M., A.J. Muller, M.H. Havlik, Y. Maru, and O.N. Witte. 1991. BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner. Cell. 66(1):161-171.
9. McWhirter, J.R., and J.Y. Wang. 1991. Activation of tyrosinase kinase and microfilament-binding functions of c-abl by bcr sequences in bcr/abl fusion proteins. Mol. Cell. Biol. 11(3):1553-1563.
10. McWhirter, J.R., D.L. Galasso, and J.Y. Wang. 1993. A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins. Mol. Cell. Biol. 13(12):7587-7595.
11. Lugo, T.G., A.M. Pendergast, A.J. Muller, and O.N. Witte. 1990. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science (Wash. DC). 247(4946):1079-1082.
12. Van Etten, R.A., P.K. Jackson, D. Baltimore, M.C. Sanders, P.T. Matsudaira, and P.A. Janmey. 1994. The COOH terminus of the c-Abl tyrosine kinase contains distinct F- and G-actin binding domains with bundling activity. J. Cell Biol. 124(3):325-340.
13. Papadopoulos, P., S.A. Ridge, C.A. Boucher, C. Stocking, and L.M. Wiedemann. 1995. The novel activation of ABL by fusion to an ets-related gene. TEL. Cancer Res. 55(1):34-38.
14. Golub, T.R., G.F. Barker, S.K. Bohlander, S.W. Hiebert, D.C. Ward, P. Bray-Ward, E. Morgan, S.C. Raimondi, J.D. Rowley, and D.O. Gilliland. 1995. Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. Proc. Natl. Acad. Sci. USA. 92(11):4917-4921.
15. Golub, T.R., A. Goga, G.F. Barker, D.E. Afar, J. McLaughlin, S.K. Bohlander, J.D. Rowley, O.N. Witte, and D.G. Gilliland. 1996. Oligomerization of the ABL tyrosine kinase by the Ets protein TEL in human leukemia. Mol. Cell. Biol. 16(8):4107-4116.
16. Okuda, K., T.R. Golub, D.G. Gilliland, and J.D. Griffin. 1996. p210BCR/ABL, p190BCR/ABL, and TEL/ABL activate similar signal transduction pathways in hematopoietic cell lines. Oncogene. 13:1147-1152.
17. Watowich, S.S., D.J. Hilton, and H.F. Lodish. 1994. Activation and inhibition of erythropoietin receptor function: Role of receptor dimerization. Mol. Cell. Biol. 14:3535-3549.
18. Andoniou, C.E., C.B. Thien, and W.Y. Langdon. 1994. Tumour induction by activated abl involves tyrosine phosphorylation of the product of the cbl oncogene. EMBO (Eur. Mol. Biol. Organ.) J. 13(19):4515-4523.
19. Matsuguchi, T., R. Salgia, M. Hallek, M. Eder, B. Druker, T. Ernst, and J.D. Griffin. 1994. She phosphorylation in myeloid cells is regulated by GM-CSF, IL-3, and Steel Factor, and is constitutively increased by p210BCR/ABL. J. Biol. Chem. 269:5016-5021.
20. Sattler, M., R. Salgia, K. Okuda, N. Uemura, M.A. Durstin, E. Pisick, G. Xu, J.L. Li, K.V. Prasad, and J.D. Griffin. 1996. The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ ABL and p210BCR/ABL to the phosphatidylinositol-3′ kinase pathway. Oncogene. 12(4):839-846.
21. D'Andrea, A.D., H.F. Lodish, and G.G. Wong. 1989. Expression cloning of the murine erythropoietin receptor. Cell. 57:277-285.
22. Ben-Neriah, Y., A. Bernards, G. Paskind, G.Q. Daley, and D. Baltimore. 1986. Alternative 5′ exons in c-abl mRNA. Cell. 44:577-586.
23. D'Andrea, A.D., A. Yoshimura, H. Youssoufian, L.I. Zon, J.W. Koo, and H.F. Lodish. 1991. The cytoplasmic region of the erythropoietin receptor contains nonoverlapping positive and negative growth-regulatory domains. Mol. Cell. Biol. 11:1980-1987.
24. Barber, D.E., J.C. DeMartino, M.O. Showers, and A.D. D'Andrea. 1994. A dominant negative erythropoietin(EPO) receptor inhibits EPO-dependent growth and blocks F-gp55-dependent transformation. Mol. Cell. Biol. 14: 2257-2265.
25. Druker, B., K. Okuda, U. Matulonis, R. Salgia, T. Roberts, and J.D. Griffin. 1992. Tyrosine phosphorylation of rasGAP and associated proteins in chronic myelogenous leukemia cell lines. Blood. 79:2215-2220.
26. Carlesso, N., D.A. Frank, and J.D. Griffin. 1996. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. J. Exp. Meet. 183(3):811-820.
27. Gishizky, M.L., and O.N. Witte. 1992. BCR/ABL enhances growth of multipotent progenitor cells but does not block their differentiation potential in vitro. Curr. Top. Microbiol. Immunol. 182:65-72.
28. Bazzoni, G., N. Carlesso, J.D. Griffin, and M.E. Hemler. 1996. Bcr/Abl expression stimulates integrin function in hematopoietic cell lines. J. Clin. Invest. 98(2):521-528.
29. Kelliher, M., A. Knott, J. McLaughlin, O.N. Witte, and N. Rosenberg. 1991. Differences in oncogenic potency but not target cell specificity distinguish the two forms of the BCR/ABL oncogene. Mol. Cell. Biol. 11(9):4710-4716.
30. Maru, Y., and O.N. Witte. 1991. The BCR gene encodes a novel serine/ threonine kinase activity within a single exon. Cell. 67(3):459-468.
31. Muller, A.J., J.C. Young, A.M. Pendergast, M. Pondel, N.R. Landau, D.R. Littman, and O.N. Witte. 1991. BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias. Mol. Cell. Biol. 11(4):1785-1792.
32. Pendergast, A.M., L.A. Quilliam, L.D. Cripe, C.H. Bassing, Z. Dai, N. Li, A. Batzer, K.M. Rabun, C.J. Der, J. Schlessinger, and M.L. Gishizky. 1993. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell. 75(1):175-185.
33. Melo, J.V. 1996. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype [editorial, comment]. Blood. 88(7):2375-2384.
34. Daley, G., and D. Baltimore. 1988. Transformation of an interleukin-3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific p210 BCR/ABL protein. Proc. Natl. Acad. Sci. USA. 85:9312.
35. Carlesso, N., J.D. Griffin, and B.J. Druker. 1994. Use of a temperature sensitive mutant to define the biological effects of the p210bcr/abl tyrosine kinase on proliferation of a factor-dependent murine myeloid cell line. Oncogene. 9:149-156.
36. Linnekin, D., G.A. Evans, A. D'Andrea, and W.L. Farrar. 1992. Association of the erythropoietin receptor with protein tyrosine kinase activity. Proc. Natl. Acad. Sci. USA. 89(14):6237-6241.
37. Damen, J., A.L. Mui, P. Hughes, K. Humphries, and G. Krystal. 1992. Erythropoietin-induced tyrosine phosphorylations in a high erythropoietin receptor-expressing lymphoid cell line. Blood. 80(8):1923-1932.
38. D'Andrea, A.D., A. Yoshimura, H. Youssoufian, L.I. Zon, J.W. Koo, and H.F. Lodish. 1991. The cytoplasmic region of the erythropoietin receptor contains nonoverlapping positive and negative growth-regulatory domains. Mol. Cell. Biol. 11(4):1980-1987.
39. Barber, D.L., J.M. Mason, T. Fukazawa, K.A. Reedquist, B.J. Druker, H. Band, and A.D. D'Andrea. 1997. Erythropoietin and interleukin-3 activate tyrosine phosphorylation of CBL and association with CRK adaptor proteins. Blood. 89(9):3166-3174.
40. Matsumoto, A., M. Masuhara, K. Mitsui, M. Yokouchi, M. Ohtsubo, H. Misawa, A. Miyajima, and A. Yoshimura. 1997. CIS, a cytokine inducible SH2 protein, is a target of the JAK-STAT5 pathway and modulates STAT5 activation. Blood. 89(9):3148-3154.
41. Krosl, J., J.E. Damen, G. Krystal, and R.K. Humphries. 1995. Erythropoietin and interleukin-3 induce distinct events in erythropoietin receptor-expressing BA/F3 cells. Blood. 85(1):50-56.
42. Shimizu, R., N. Komatsu, Y. Nakamura, H. Nakauchi, Y. Nakabeppu, and Y. Miura. 1996. Role of c-jun in the inhibition of erythropoietin receptor-mediated apoptosis. Biochem. Biophys. Res. Commun. 222(1):1-6.
43. Gobert, S., F. Porteu, S. Pallu, O. Muller, M. Sabbah, I. Dusanter-Fourt, G. Courtois, C. Lacombe, S. Gisselbrecht, and P. Mayeux. 1995. Tyrosine phosphorylation of the erythropoietin receptor: role for differentiation and mitogenic signal transduction. Blood. 86(2):598-606.
44. Matulonis, U., R. Salgia, K. Okuda, B. Druker, and J.D. Griffin. 1993. Interleukin-3 and p210 BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line. Exp. Hematol. 21(11):1460-1466.
45. Gordon, M.Y., C.R. Dowding, G.P. Riley, J.M. Goldman, and M.F. Greaves. 1987. Altered adhesive interactions with marrow stroma of haematopoietic progenitor cells in chronic myeloid leukaemia. Nature (Lond.). 328(6128):342-344.
46. Gordon, M.Y., C.R. Dowding, G.P. Riley, J.M. Goldman, and M.F. Greaves. 1989. Adhesive defects in chronic myeloid leukemia [review]. Curr. Top. Microbiol. Immunol. 149:151-155.
47. Verfaillie, C.M., J.B. McCarthy, and P.B. McGlave. 1992. Mechanisms underlying abnormal trafficking of malignant progenitors in chronic myelogenous leukemia. J. Clin. Invest. 90:1232-1241.
48. Salgia, R., J.-L. Le, D.S. Ewaniuk, W. Pear, E. Pisick, S.A. Burky, T. Ernst, M. Sattler, L.B. Chen, and J.D. Griffin. 1997. BCR/ABL induces multiple abnormalities of cytoskeletal function. J. Clin. Invest. 100:46-57.
49. Salgia, R., M. Sattler, E. Pisick, J.L. Li, and J.D. Griffin. 1996. p210BCR/ABL induces formation of complexes containing focal adhesion proteins and the protooncogene product p120c-Cbl. Exp. Hematol. 24(2):310-313.
50. Salgia, R., B. Brunkhorst, E. Pisick, J.-L. Li, S.H. Lo, L.B. Chen, and J.D. Griffin. 1995. Increased tyrosine phosphorylation of focal adhesion proteins in myeloid cell lines expressing p210BCR/ABL. Oncogene. 11:1149-1155.
51. Cuzick, J. 1985. A Wilcoxon-type test for trend. Stat. Med. 4:87-90.